Transgender women (TW) face one of the highest HIV burdens worldwide. In Malaysia, 12.4% of TW are HIV infected, ∼30-fold higher than in the Malaysian adult population. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy, however, little is known about TW's willingness to use PrEP or their preferences for receiving PrEP. This study examined the correlates of Malaysian TW's willingness to use PrEP and their attitudes and preferences related to delivery of PrEP and PrEP-related care.
Methods:
Between June and August 2017, 361 TW in Malaysia completed an online survey about their knowledge of and willingness to use PrEP for HIV prevention.
Results:
Only 20.2% of participants had ever previously heard of PrEP and none were currently taking PrEP. The majority (82.5%) expressed high willingness to take PrEP and most participants met the World Health Organization (WHO) indication for PrEP (82.3%). In the multivariate model, lifetime hormone use, prior postexposure prophylaxis use, and having completed a high school education were associated with higher willingness to use PrEP, while injection drug use, older age, and Chinese ethnicity were associated with lower PrEP willingness.
Conclusion:
TW in Malaysia are highly willing to use PrEP for HIV prevention. Differences in willingness to use PrEP identified by education, ethnicity, substance abuse, and age suggest different strategies may be needed to scale-up PrEP for this diverse community of TW.
Get full access to this article
View all access options for this article.
References
1.
BaralSD, PoteatT, StrömdahlS, et al.Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13:214–222.
2.
PoteatT, ScheimA, XavierJ, et al.Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016; 72(Suppl. 3):S210–S219.
3.
Malaysia Ministry of Health. National Strategic Plan for Ending AIDS: 2016–2030. Putrajaya, Malaysia: Malaysia Ministry of Health, 2015.
4.
WickershamJA, GibsonBA, BazaziAR, et al.Prevalence of human immunodeficiency virus and sexually transmitted infections among cisgender and transgender women sex workers in Greater Kuala Lumpur, Malaysia: results from a respondent-driven sampling study. Sex Transm Dis. 2017; 44:663–670.
5.
PoteatT, MalikM, ScheimA, ElliottA. HIV prevention among transgender populations: knowledge gaps and evidence for action. Curr HIV/AIDS Rep. 2017; 14:141–152.
6.
PoteatT, WirtzAL, RadixA, et al.HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015; 385:274–286.
7.
Force USPST. Prevention of human immunodeficiency virus (HIV) infection: pre-exposure prophylaxis. https://wwwuspreventiveservicestaskforceorg/Page/Document/draft-recommendation-statement/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis Accessed December3, 2018.
8.
GallantJE, DeJesusE, ArribasJR, et al.Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354:251–260.
9.
RistigMB, CrippinJ, AbergJA, et al.Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002; 186:1844–1847.
10.
WangZ, LauJTF, YangX, et al.Acceptability of daily use of free oral pre-exposure prophylaxis (PrEP) among transgender women sex workers in Shenyang, China. AIDS Behav. 2017; 21:3287–3298.
11.
OldenburgCE, LeB, ToanT, et al.HIV pre-exposure prophylaxis indication and readiness among HIV-uninfected transgender women in Ho Chi Minh City, Vietnam. AIDS Behav. 2016; 20(Suppl. 3):365–370.
12.
ZablotskaI, GrulichAE, PhanuphakN, et al.PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers. J Int AIDS Soc. 2016; 19(7,Suppl. 6):21119.
13.
LimSH, MburuG, BourneA, et al.Willingness to use pre-exposure prophylaxis for HIV prevention among men who have sex with men in Malaysia: findings from an online survey. PLoS One. 2017; 12:e0182838.
14.
Centers for Disease Control and Prevention. Pre-exposure prophylaxis for the prevention of HIV infection in the United States: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf Accessed November5, 2017.
15.
LeeAE, ChokkanathanS. Factor structure of the 10-item CES-D scale among community dwelling older adults in Singapore. Int J Geriatr Psychiatry. 2008; 23:592–597.
16.
Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: BRFSS 2006 Survey Data and Documentation—Questionnaire. https://www.cdc.gov/brfss/annual_data/annual_2006.htm. Accessed November5, 2017.
17.
World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment, and care for key populations. Geneva, Switzerland: World Health Organization, 2016.
18.
DraperBL, OoZM, TheinZW, et al.Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc. 2017; 20:1–10.
19.
YangD, ChariyalertsakC, WongthaneeA, et al.Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One. 2013; 8:e76650.
20.
HoaglandB, MoreiraRI, De BoniRB, et al.High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017; 20:1–14.
21.
KuhnsLM, ReisnerSL, MimiagaMJ, et al.Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women. AIDS Behav. 2016; 20:1470–1477.
22.
PeinadoJ, LamaJR, GaleaJT, et al.Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Peru. J Int Assoc Provid AIDS Care. 2013; 12:278–283.
23.
ZalazarV, AristeguiI, KerrT, et al.High willingness to use HIV pre-exposure prophylaxis among transgender women in Argentina. Transgend Health. 2016; 1:266–273.
24.
WhiteD, StephensonR. Identity formation, outness, and sexual risk among gay and bisexual men. Am J Mens Health. 2014; 8:98–109.
25.
PitpitanEV, SmithLR, Goodman-MezaD, et al.“Outness” as a moderator of the association between syndemic conditions and HIV risk-taking behavior among men who have sex with men in Tijuana, Mexico. AIDS Behav. 2016; 20:431–438.
26.
ChakrapaniV, NewmanPA, ShunmugamM, et al.Acceptability of HIV pre-exposure prophylaxis (PrEP) and implementation challenges among men who have sex with men in India: a qualitative investigation. AIDS Patient Care STDS. 2015; 29:569–577.
27.
YoungI, McDaidL. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014; 18:195–216.
28.
IsmailMN. Obesity in Malaysia. Obes Rev. 2002; 3:203–208.
29.
ShannonK, StrathdeeSA, GoldenbergSM, et al.Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet. 2015; 385:55–71.
30.
SeveliusJM, DeutschMB, GrantR. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016; 19(7(Suppl. 6)):21105.
31.
SeveliusJM, KeatleyJ, CalmaN, ArnoldE. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016; 11:1060–1075.
32.
GaleaJT, KinslerJJ, SalazarX, et al.Acceptability of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011; 22:256–262.
33.
HoltM. HIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region and the Americas. Sexual Health. 2013; 11:166–170.
